Ortho-McNeil Pharmaceutical, Inc. Resolves Investigation of Past TOPAMAX(R) Marketing and Promotional Activities

Published: Apr 29, 2010

TITUSVILLE, N.J., April 29 /PRNewswire/ -- Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI) today announced an agreement with the U.S. Attorney's Office for the District of Massachusetts, the U.S. Department of Justice, and other federal agencies to resolve a previously reported government investigation of past U.S. marketing and promotional practices for TOPAMAX® (topiramate), an antiepileptic and migraine prevention prescription medicine.

Back to news